Treatment of 37 patients with anaplastic carcinoma of the thyroid

Kobayashi, Tetsuro; Asakawa, Hideki; Umeshita, Koji; Takeda, Tsutomu; Maruyama, Hiroki; Matsuzuka, Fumio; Monden, Morito

doi:10.1002/(sici)1097-0347(199601/02)18:1<36::aid-hed5>3.0.co;2-#

Cited by 116 publications

(77 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This carcinoma is highly malignant, nonencapsulated, extends widely, and has a poor prognosis [6][7][8][9][10][11]. In several anaplastic thyroid carcinoma cell lines, many cytokines such as granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), IL-1a, IL-6, and TGF-a are produced [12][13][14][15].…”

mentioning

confidence: 99%

Anaplastic Thyroid Carcinoma with Humoral Hypercalcemia of Malignancy (HHM): An Autopsy Case Report

2004

View full text Add to dashboard Cite

Abstract. An 84-year-old woman was admitted to our hospital for the examination and treatment of painful right thyroid swelling on August 2, 2002. Thyroid ultrasonography showed a mass of about 6 cm in diameter at the right thyroid lobe. Aspiration biopsy cytology (ABC) of her mass showed a thyroid carcinoma. Her neck mass was cold on 123 I scintigraphy and hot on both early-and delayed-phase 201 Tl scintigraphy. Whole body 67 Ga scintigraphy scan showed a strong hot accumulation in the area from the right thyroid lobe to the right lateral lobe. Multiple lung tumors were observed from chest computed tomography (CT) scans. She was diagnosed as having an anaplastic thyroid carcinoma with metastatic lung tumors. As her thyroid carcinoma was inoperable, percutaneous injection therapy of lipiodol and ethanol (lip-PEIT) against the primary thyroid carcinoma was performed twice a week. However, the thyroid carcinoma gradually enlarged and oppressed her trachea. Two months after the initiation of lip-PEIT, parathyroid hormone-related protein (PTHrP)-dependent hypercalcemia was diagnosed because serum levels of calcium, phosphate and intact-PTHrP were 2.72 mmol/l (10.9 mg/dl), 0.71 mmol/l (2.2 mg/dl), 3.2 pmol/l, respectively. The hypercalcemia was reduced by the use of pamidronate. After one week she died of an airway obstruction caused by the developing thyroid carcinoma. Carcinoma cells with a mixed papillary and squamoid pattern were positively stained immunohistochemically by anti-PTHrP(1-34) antisera. Herein, we report a rare autopsy case of a PTHrP-producing thyroid carcinoma.

show abstract

mentioning

confidence: 99%

Anaplastic Thyroid Carcinoma with Humoral Hypercalcemia of Malignancy (HHM): An Autopsy Case Report

2004

View full text Add to dashboard Cite

show abstract

“…Although the prognosis of ATC has been extremely poor despite multimodal treatments, it has been reported that radical surgery significantly extended the survival period in patients with resectable ATC [5,[12][13][14]. Several authors have shown that <5 cm as the size of the primary lesion and complete resection are positive prognostic factors in ATC patients [5,12,13].…”

Section: Discussionmentioning

confidence: 99%

“…Several authors have shown that <5 cm as the size of the primary lesion and complete resection are positive prognostic factors in ATC patients [5,12,13]. Ito et al [14] treated five ATC patients who developed anaplastic transformation in regional lymph nodes.…”

Section: Discussionmentioning

confidence: 99%

Anaplastic Thyroid Carcinoma Treated with Lenvatinib

et al. 2017

View full text Add to dashboard Cite

Anaplastic thyroid carcinoma (ATC), which accounts for 1%-2% of all malignant tumors of the thyroid, is known to be highly resistant to any therapy and has a 1-year survival rate of 5%-20% [1][2][3]. ATC patients are limited in number, and most die within 6 months after diagnosis, making it difficult to establish a standard treatment protocol. Multimodal therapy including surgery, radiotherapy and chemotherapy has been introduced, but survival times remain poor [4][5][6].The use of molecular-targeted drugs as cancer therapy has been rapidly increasing over the past decade. Lenvatinib, a new molecular-targeted anticancer drug, is a multi-targeted receptor tyrosine kinase inhibitor that inhibits the activities of vascular endothelial growth factor receptors, fibroblast growth factor receptors, platelet-derived growth factor receptors, KIT, and RET [7,8]. Lenvatinib exerts its anticancer activity via the suppression of tumor angiogenesis, and it is generally indicated for unresectable radioiodine-refractory differentiated thyroid cancers [9]. However, the evidence of the clinical effect of this drug on ATC is very limited. We herein report a case of ATC with local recur- Kurume Medical Journal, 64, 00-00, 2017 Summary: Objective: We report a case of anaplastic thyroid carcinoma (ATC) with local recurrence and distant metastasis that responded very well to treatment with lenvatinib, a new molecular-targeted anticancer drug. Case Report: A 91-year-old Japanese woman presented with a 5-month history of a painless mass in her left anterior neck. She had a past history of total thyroidectomy and neck dissection for papillary carcinoma of the thyroid. Here she underwent neck dissection, and the histopathological diagnosis was lymph node metastasis of papillary carcinoma with anaplastic transformation. Five months later, a cervical lymph node swelled up again.Computed tomography demonstrated an enhanced mass in the neck and multiple nodules in both lungs. Recurrent ATC with multiple lung metastases was diagnosed, and molecular-targeted therapy with lenvatinib was initiated. The neck tumor reduced in 1 week, and the pulmonary nodules became completely hollow within 1 month. However, we had to discontinue lenvatinib because of severe side effects including high blood pressure, hypocalcemia, and hypoalbuminemia. Soon after discontinuation, the side effects subsided, but the tumor rapidly regrew. The patient died of lymphangiosis carcinomatosa 6 days after discontinuation. Conclusion: Although recent advances in molecular-targeted therapy have provided powerful cancer therapy tools, the negative side of this therapy must be addressed.

show abstract

“…Furthermore, Wnt/b-catenin pathway-based adenovirus therapy P H Abbosh et al treatment with HILMI resulted in significant inhibition of tumor growth and, in some animals, long-term tumor growth suppression. The use of the thyroglobulin promoter for conditional expression of therapeutic genes or conditional replication has been shown to be effective in cells which express this marker, [37][38][39][40][41] however, undifferentiated thyroid cancers often have reduced or absent thyroglobulin. To our knowledge, this is the first report to use transcriptionally driven replication specifically for undifferentiated thyroid cancer.…”

Section: Discussionmentioning

confidence: 99%

A conditionally replicative, Wnt/β-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer

Abbosh

et al. 2007

Cancer Gene Ther

View full text Add to dashboard Cite

Thyroid cancer affects between 10 000 and 15 000 people per year in the US. Typically, this disease can be controlled with surgical resection and radioiodide treatment. However, resistance to these conventional therapies is observed in some patients, who develop intractable anaplastic thyroid cancer (ATC), for which no effective therapies exist. Recently, a sizable fraction of undifferentiated or poorly differentiated thyroid cancers were shown to contain mutations in b-catenin, an oncogenic protein involved in the etiology of cancers of many tissues. We developed a conditionally replicative adenovirus (named 'HILMI') which, by virtue of TCF response elements drives E1A and E1B expression, replicates specifically in cells with an active Wnt/b-catenin pathway. We show that several thyroid cancer cell lines, derived from undifferentiated or anaplastic tissues and possessing an active Wnt/b-catenin pathway, are susceptible to cell killing by HILMI. Furthermore, viral replication in ATC cells as xenograft tumors in nude mice was observed, and prolonged survival of mice with ATC tumors was observed following administration of the HILMI therapeutic vector. The results warrant further development of this therapeutic approach for ATC patients.

show abstract

Treatment of 37 patients with anaplastic carcinoma of the thyroid

Cited by 116 publications

References 9 publications

Anaplastic Thyroid Carcinoma with Humoral Hypercalcemia of Malignancy (HHM): An Autopsy Case Report

Anaplastic Thyroid Carcinoma with Humoral Hypercalcemia of Malignancy (HHM): An Autopsy Case Report

Anaplastic Thyroid Carcinoma Treated with Lenvatinib

A conditionally replicative, Wnt/β-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer

Contact Info

Product

Resources

About